Enarodustat + CsA vs CsA in Newly Diagnosed TD-NSAA

Exclusion Criteria

• •1. Had other primary or secondary bone marrow failure (BMF) diseases, such as Fanconi anemia, congenital keratinization disorder, etc.;
• •2. With evidence of clonal hematological bone marrow diseases (MDS, AML) in cytogenetics;
• •3. PNH clone ≥ 50%;
• •4. Received HSCT before enrollment;
• •5. Previously used immunosuppressive treatments such as ATG, CsA, TPO receptor agonists (TPO-RAs), roxadustat;
• •6. Allergic or intolerant to enarodustat or CsA;
• •7. Pregnant or lactating patients;
• •8. Severe bleeding or infection that cannot be controlled by standard treatment;
• •9. Complicated with malignant tumors;
• •10. Participated in other clinical trials within 3 months;
• •11. Patients considered not suitable to participate in this study by the investigator.